Would you treat a postmenopausal women with high grade T2N0 ER-, PR+, HER2- invasive ductal carcinoma with upfront surgery or neoadjuvant chemotherapy?

Topics: Breast Cancer • Medical Oncology • MD Anderson • NCI-CCC Tumor Board Question • HR+ • NCI-CCC Breast Tumor Board Question

ER <1%; PR 45%, Her2 negative by IHC and FISH. Grade 3, Ki67: 80%.

Answer from: Medical Oncologist at Academic Institution

I'd conduct a conversation about NAC, but it isn't clear to me that NAC would change anything for this patient. PR 45% does not qualify as "functionally triple negative" in my book, so I'd consider this still HR+. I would not offer more than AC-T whether NAC or adjuvant. Additionally, I wouldn't off...

Comments

Medical Oncologist at Sarah Cannon Cancer Institute at Menorah Medical Center
I have recently had a case with ER -ve, PR 1-10%, ...

Medical Oncologist at Banner MD Anderson Cancer Center
We are not sure if ER-, PR+ breast cancer is a rea...

Related Questions